Status: Recruiting
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
Participants needed: 18
Trial details
Phase: Phase 2Age: 0-30Biological sex: AllType: InterventionalSponsor: Allison O'Neill, MDUpdated: Feb 24, 2026Locations: 5
Eligibility criteria
Age: Patients must be <30 years of age at the time of study enrollment. [+29]
Participants who are receiving any other investigational agents are not eligible... [+9]